Middle-aged, Male, and Mildly Annoyed: Why I Stopped Going to Startup Events
If you’ve read this blog—ramblings, thought-leadership, or the digital equivalent of shouting into the void—you might be
Guide to Critically Assessing Early-Stage Pharma and Biotech Pitch Decks
1. Pricing and Reimbursement Pressures
1.1 Early Pricing Negotiations
* The New Reality:
* Payers and HTA bodies, particularly in Europe,
IPOs: Europe’s Public Markets Problem
For biotech companies, the IPO is like a debutante ball—a grand public coming-out party where you hope to dazzle
The Private Market Data Illusion: Lies, Damn Lies, and PitchBook Statistics
Venture capital and private equity thrive on numbers—IRRs, TVPIs, MOICs—each acronym an attempt to quantify success in an
What I Learned Losing a Million Dollars (And Why Taleb Approves)
There are many books about how to make money. There are far fewer about how people actually lose it. What
Feeding on the Fine Print: What The Art of Vulture Investing Taught Me About Survival
There are very few finance books that you can read without needing a double espresso or a minor existential crisis
What Is Happening in Drug Discovery?
The integration of artificial intelligence (AI) into drug discovery is reshaping pharmaceutical development, prompting regulatory bodies to adapt their frameworks
The Art of "Building" a VC Track Record: How to Be Economical With the Truth
Venture capital, like any industry where past success is difficult to verify, has a long tradition of being economical with
The “Game-Changing” Illusion: How Pharma Spins Mediocre Drugs Into Miracles
Every year, the pharma industry rolls out its latest batch of “game-changing,” “best-in-class,” and “first-in-class” therapies, showering them with press
Venture Debt: A Deal With the Devil You Know
capable of wreaking havoc if overindulged. For biotech founders staring down the barrel of cash burn and trial delays, it
